SCHEMBL5455068

SCHEMBL5455068

O=C(Nc1cccs1)N1CCN(c2ccc3c(c2)CCN(C2CCCC2)CC3)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.49
TMEM97 Q5BJF2 5/20 0.47
SIGMAR1 Q99720 5/20 0.47
HRH3 Q9Y5N1 5/20 0.47
DRD3 P35462 3/20 0.47
HTR1A P08908 2/20 0.47
HRH2 P25021 2/20 0.47
HRH1 P35367 2/20 0.47
CHRM4 P08173 1/20 0.47
CHRM5 P08912 1/20 0.47
ADRA2A P08913 1/20 0.47
ADRA2B P18089 1/20 0.47
ADRA1D P25100 1/20 0.47
HTR2A P28223 1/20 0.47
HTR2C P28335 1/20 0.47
ADRA1A P35348 1/20 0.47
ADRA1B P35368 1/20 0.47
HTR2B P41595 1/20 0.47
HTR5A P47898 1/20 0.47
ADRA2C P18825 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5461750 0.83 ALDH1A1 (0.60) GAATMEM97SIGMAR1HRH3DRD3
SCHEMBL5464346 0.82 FAAH (0.55) TMEM97SIGMAR1HRH3DRD3HTR1A
SCHEMBL5458802 0.78 CA12 (0.56) TMEM97SIGMAR1HRH3DRD3HTR1A
SCHEMBL5451342 0.78 CA12 (0.56) GAAHRH3HTR1AHTR2AHTR2C
SCHEMBL5472459 0.77 TMEM97 (0.53) TMEM97SIGMAR1HRH3DRD3HTR1A
SCHEMBL5451491 0.77 TMEM97 (0.53) TMEM97SIGMAR1HRH3DRD3HTR1A
SCHEMBL5465885 0.76 KDM4E (0.60) TMEM97SIGMAR1HRH3DRD3HTR1A
SCHEMBL5459210 0.76 MAPT (0.57) GAAHRH3HTR1AMAPTGFER
SCHEMBL5466133 0.76 MAPT (0.57) TMEM97SIGMAR1HRH3DRD3HTR1A
SCHEMBL4772344 0.76 MAPT (0.58) TMEM97SIGMAR1HRH3HTR1AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070185089-A1 Benzazepine derivatives for the treatment of neurological and psychiatric disorders GLAXO GROUP LIMITED (GB) 2007-08-09 US claimed
US-20070185089-A1 Benzazepine derivatives for the treatment of neurological and psychiatric disorders GLAXO GROUP LIMITED (GB) 2007-08-09 US disclosed
US-20070185089-A1 Benzazepine derivatives for the treatment of neurological and psychiatric disorders GLAXO GROUP LIMITED (GB) 2007-08-09 US disclosed
US-20070185089-A1 Benzazepine derivatives for the treatment of neurological and psychiatric disorders GLAXO GROUP LIMITED (GB) 2007-08-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185089-A1 Benzazepine derivatives for the treatment of neurological and psychiatric disorders CNR2, GRIN2C, GRIN2B GAA 1910/4885TMEM97 486/4885SIGMAR1 129/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.